Clinical Report: Tildrakizumab 200 mg for Managing Complex Psoriasis

Overview

This case series presents data on the use of tildrakizumab 200 mg in patients with moderate-to-severe psoriasis, particularly those with multiple comorbidities and high disease burden. Most patients achieved PASI90 or PASI100 responses within 4–12 weeks.

Background

Psoriasis is a chronic inflammatory skin condition affecting millions globally, often complicated by comorbidities such as obesity and cardiovascular diseases. Effective management is crucial, especially in patients with high disease burden and prior treatment failures. Tildrakizumab, an anti-IL-23 monoclonal antibody, is used in these challenging cases.

Data Highlights

Key Findings

• Tildrakizumab 200 mg led to PASI90 or PASI100 responses in most patients within 4–12 weeks.
• Complete clearance (PASI100) was observed in four out of six patients.
• Patients had multiple comorbidities, including cardiometabolic conditions and high body weight.
• Treatment effectiveness was maintained over approximately 24 months.
• The safety profile of tildrakizumab was favorable throughout the treatment period.

Clinical Implications

Dermatologists should consider the specific clinical profiles of patients with moderate-to-severe psoriasis when selecting treatment options.

Conclusion

Tildrakizumab 200 mg demonstrates effectiveness in managing complex psoriasis cases.

Related Resources & Content

1. Dermatology and Therapy, 2026 -- Tildrakizumab Improves Disease Severity and Patient-Reported Outcomes in Moderate-to-Severe Chronic Plaque Psoriasis: A Prospective Real-World Study
2. Dermatology and Therapy, 2026 -- Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks
3. Dermatology and Therapy, 2026 -- Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial
4. EUROGUIDERM GUIDELINE FOR THE SYSTEMIC, 2025 -- Guidance and labeling
5. Ilumetri 200 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)
6. conexiant — Combo Therapy for Psoriasis With Obesity
7. Real-World Effectiveness and Safety of Tildrakizumab in Moderate-to-Severe Psoriasis: A Multicenter Experience in the Basque Country
8. EUROGUIDERM GUIDELINE FOR THE SYSTEMIC
9. Ilumetri 200 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc) | 13908